# OnCo record cup-favourable-subsets (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/cup-favourable-subsets/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "cup-favourable-subsets" ;
  schema:name "Cancer of unknown primary, favourable subsets"@en ;
  schema:alternateName "Favourable-risk CUP"@en, "Treatable CUP subsets"@en, "CUP with a presumed primary"@en, "Specific CUP syndromes"@en ;
  schema:description "Favourable subsets of cancer of unknown primary are the roughly one in five cases where the pattern of spread, the microscope appearance or blood markers point strongly to a particular cancer even though no primary can be found. They are treated as that cancer would be, for example breast cancer for a woman with cancer only in armpit nodes, and many are curable or controllable for years."@en ;
  schema:url <https://onco.cc/cancers/cup-favourable-subsets/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cancer_of_unknown_primary_origin> ;
  schema:citation <https://doi.org/10.1016/j.annonc.2022.11.013>, <https://en.wikipedia.org/wiki/Cancer_of_unknown_primary_origin> ;
  onco:tag "subtype-page", "site-agnostic" ;
  onco:related <https://onco.cc/cancers/cup-unfavourable/>, <https://onco.cc/cancers/cancer-of-unknown-primary/>, <https://onco.cc/cancers/extragonadal-germ-cell-tumour/>, <https://onco.cc/cancers/extrapulmonary-nec/> ;
  onco:technologies <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/technologies/sbrt/>, <https://onco.cc/technologies/germ-cell-tumour-markers/> ;
  onco:drugs <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/lutathera/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/terms/primary-tumour/>, <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/terms/debulking/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-esmo-cancer-of-unknown-primary-guideline-ann-oncol-2023/>, <https://onco.cc/key-papers/paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019/> ;
  onco:pipeline <https://onco.cc/technologies/cgp/>, <https://onco.cc/technologies/methylation-profiling/>, <https://onco.cc/technologies/liquid-biopsy/> ;
  onco:standardOfCare <https://onco.cc/technologies/histopathology-ihc/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/technologies/ct/>, <https://onco.cc/technologies/pet-ct/>, <https://onco.cc/terms/tumour-markers/>, <https://onco.cc/technologies/germ-cell-tumour-markers/>, <https://onco.cc/terms/lymphadenectomy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/terms/debulking/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/chemoradiation/>, <https://onco.cc/terms/hpv-p16/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/etoposide/>, <https://onco.cc/technologies/germ-cell-tumour-markers/>, <https://onco.cc/drugs/platinum-etoposide/>, <https://onco.cc/drugs/octreotide-lanreotide/>, <https://onco.cc/drugs/lutathera/>, <https://onco.cc/technologies/sbrt/> .